Clinical trials: Newly Diagnosed Breast Cancer
Neoplasms, Breast
Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer
This Study was designed to determine how effective and safe a new investigational drug, lapatinib, is in combination with paclitaxel in treating patients with newly diagnosed inflammatory breast cancer.
- Trial name
- NCT00111787
- Testing
- Lapatinib, Paclitaxel
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 49 people
- Sponsor
- GlaxoSmithKline
HER2 Positive Early or Locally Advanced Breast Cancer
A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer
A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin® in Women with Newly…
- Trial name
- NCT02149524
- Testing
- Herceptin (trastuzuamb), SB3 (proposed trastuzumab biosimilar)
- Where
- Czechia
- Volunteers
- 875 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Breast Cancer
A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer
The primary objective of the study is to evaluate changes in the expression of targeted biomarkers in invasive breast cancer tissue before and after SNDX-275 administration.
- Trial name
- NCT00754312
- Testing
- SNDX-275
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Syndax Pharmaceuticals
Breast Carcinoma, Metastatic Breast Cancer
Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for newly Diagnosed Breast Carcinoma patients with distant metastases
- Conditions
- Breast Carcinoma, Metastatic Breast Cancer, Invasive Breast Cancer, Distant Metastases.Pathology
- Trial name
- NCT03970967
- Testing
- Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Russia
- Volunteers
- 1 people
- Sponsor
- Alpha Tau Medical LTD.
Breast Cancer
Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer
Enrolled women will undergo a bilateral Contrast-Enhanced Breast Magnetic Resonance Imaging (CE-BMRI) as per usual clinical practice within 30 days of breast cancer diagnosis.
- Trial name
- NCT01303419
- Testing
- CE-BMRI, DE-CEDM
- Where
- 5 sites in United States, Belgium and 3 more
- Volunteers
- 224 people
- Sponsor
- GE Healthcare
Glioblastoma, Melanoma Stage IV
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors.
- Conditions
- Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
- Trial name
- NCT04478279
- Testing
- ST101, Temozolomide, Radiation
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 125 people
- Sponsor
- Sapience Therapeutics
Breast Cancer
A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis
This open-label, randomized, parallel arm study will evaluate the effect of capecitabine administered concurrently with WBRT and as maintenance therapy in participants with breast cancer and newly diagnosed brain metastases.
- Trial name
- XERAD (NCT00977379)
- Testing
- WBRT, Capecitabine, Standard of Care
- Where
- 16 sites in France
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
HER2-positive Newly Diagnosed, Primary Breast Cancer
NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer
This randomized, parallel cohort, two stage, double-blind, placebo-controlled study evaluated the oral PI3K inhibitor BKM120 in combination with trastuzumab and paclitaxel in HER2-positive, PIK3CA wild-type and PIK3CA mutant…
- Trial name
- NeoPHOEBE (NCT01816594)
- Testing
- BKM120, Trastuzumab, Paclitaxel
- Where
- 7 sites in Australia, Austria and 2 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
A Prospective, Multicenter, Non-Interventional Study of Primary Data Collection, Designed to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcomes in Patients with Breast Cancer in Latin America.
- Trial name
- NCT04158258
- Testing
- Bevacizumab, Trastuzumab, Ado-trastuzumab emtamsine
- Where
- 30 sites in Argentina, Brazil and 8 more
- Volunteers
- 2,907 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer
Primary Objective: To determine whether amcenestrant given at 2 different doses improved the antiproliferative activity when compared to letrozole.
- Trial name
- AMEERA-4 (NCT04191382)
- Testing
- Amcenestrant (SAR439859), Letrozole
- Where
- 32 sites in United States, Belgium and 7 more
- Volunteers
- 105 people
- Sponsor
- Sanofi
Breast Cancer
Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
The purpose of this study is to evaluate fulvestrant in the preliminary stage of breast cancer treatment and assess the relationship between dose, exposure, degree of reduction in tumor markers, and efficacy in postmenopausal…
- Trial name
- NCT00093002
- Testing
- Fulvestrant
- Where
- 31 sites in United States, Austria and 4 more
- Volunteers
- 179 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer
Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
This is a Phase 1b/2 study. In Phase 1b portion, subjects will know the treatment they are receiving . Subjects will receive U3-1287 with trastuzumab plus paclitaxel .
- Trial name
- NCT01512199
- Testing
- U3-1287, Trastuzumab, Paclitaxel
- Where
- 8 sites in Argentina, Chile
- Volunteers
- 29 people
- Sponsor
- Daiichi Sankyo
Breast Cancer, Recurrent Breast Cancer
A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly Patients.
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of newly diagnosed or Recurrent Breast Carcinoma in frail or elderly patients.
- Conditions
- Breast Cancer, Recurrent Breast Cancer, Breast Carcinoma
- Trial name
- NCT06202118
- Testing
- Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Alpha Tau Medical LTD.
Breast Cancer
Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
This is a Phase 1, open-label, dose escalation study in women with primary, non-recurrent breast cancer undergoing surgery. AVB-620 will be administered prior to surgery.
- Trial name
- NCT02391194
- Testing
- AVB-620
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Avelas Biosciences, Inc.
Breast Cancer, Diagnostic Imaging
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI
The purpose of this study is to look at the efficacy (how does it work) and safety of gadobutrol when used for obtaining MR images of both breasts.Women with a recent diagnosis of breast cancer by mammogram (X-ray examination of…
- Trial name
- NCT01067976
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Where
- 40 sites in United States, Argentina and 7 more
- Volunteers
- 446 people
- Sponsor
- Bayer
Breast Cancer
Exploratory Study to Assess the Short Term Intratumoural and Peripheral Effects of BN83495 in Postmenopausal Women With Newly Diagnosed Breast Cancer
This trial will assess the intratumoural pharmacological activity of BN83495 by changes in intratumoural levels of sex hormones and associated inhibition of steroid sulphatase (STS) activity.
- Trial name
- NCT01230970
- Testing
- BN83495
- Where
- Norway
- Volunteers
- 2 people
- Sponsor
- Ipsen
Breast Cancer
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
The purpose of this study is to look at the efficacy (how does it work) and safety of gadobutrol when used for obtaining MR images of both breasts.Women with a recent diagnosis of breast cancer by mammogram (X-ray examination of…
- Trial name
- GEMMA 2 (NCT01104584)
- Testing
- Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- Where
- 48 sites in United States, Argentina and 7 more
- Volunteers
- 460 people
- Sponsor
- Bayer
Advanced Ovarian Cancer
A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer
This study will collect the data from existing patient medical records at US cancer centers. The study will include patients with BRCAwt ovarian cancer who have been prescribed first line (1L) olaparib maintenance treatment.
- Trial name
- FLAME (NCT05775549)
- Testing
- None (Observational Study)
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Leptomeningeal Carcinomatosis, Leptomeningeal Metastases
ANG1005 in Leptomeningeal Disease From Breast Cancer
This is an open-label Phase 3 study to see if ANG1005 can prolong survival compared to a Physician Best Choice control in HER2-negative breast cancer patients with newly diagnosed leptomeningeal disease and previously treated…
- Conditions
- Leptomeningeal Carcinomatosis, Leptomeningeal Metastases, Brain Metastases, HER2-negative Breast Cancer
- Trial name
- ANGLeD (NCT03613181)
- Testing
- ANG1005, Physician's Best Choice
- Volunteers
- 150 people
- Sponsor
- Angiochem Inc